Tremelimumab, a monoclonal antibody that blocks CTLA-4, was tested for the antitumor and antiviral effect in patients with HCC and chronic infections of HCV in an open label, non-randomized phase II trial (NCT 01008358, Table 1) (51). Here, CTLA4 is linked to hepatocellular carcinoma.